1.2
1.20 (-3.88%)
As of Mar 06, 2024
Sellas Life Sciences Group, Inc. [SLS]
Source:
Company Overview
We are a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S and nelipepimut-S.
Country | United States |
Headquarters | new york, new york |
Phone Number | 6462005278 |
Industry | manufacturing |
CEO | Angelos M. Stergiou |
Website | www.sellaslifesciences.com |